A M DHOPLE
Overview
Explore the profile of A M DHOPLE including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
68
Citations
120
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
DHOPLE A, Namba K
J Chemother
. 2003 Apr;
15(1):47-52.
PMID: 12678414
Efficacy of a new fluoroquinolone, sitafloxacin (DU-6859a), against Mycobacterium ulcerans was evaluated in vivo using the mouse footpad system. The growth of M. ulcerans in mouse footpads was completely inhibited...
2.
DHOPLE A
Arzneimittelforschung
. 2001 Jul;
51(6):501-5.
PMID: 11455683
The antibacterial effects of a new benzoxazinorifamycin, KRM-1648 (3'-hydroxy-5'-(4-isobutyl-1-piperazinyl, CAS 129791-92-0), against Mycobacterium ulcerans were evaluated in vivo in mouse foot pads, and the results were compared against those obtained...
3.
Koodie L, DHOPLE A
Microbios
. 2001 May;
104(409):167-75.
PMID: 11327111
Outbreaks of diarrhoea and haemolytic uraemic syndrome have been associated with the consumption of apple cider and apple juice. The organism implicated in these outbreaks has been Escherichia coli O157:H7,...
4.
DHOPLE A
J Antimicrob Chemother
. 2001 Jan;
47(1):93-6.
PMID: 11152437
Development of new treatments against Mycobacterium ulcerans infection has become crucial because of its wide-scale prevalence throughout the world. The effects of dihydrofolate reductase inhibitors, used either singly or in...
5.
DHOPLE A
Int J Antimicrob Agents
. 2001 Jan;
17(1):57-61.
PMID: 11137650
The antimicrobial effect of a benzoxazinorifamycin, KRM-1648, either alone or in combination with ofloxacin, was evaluated in vitro against two type strains and six clinical isolates of Mycobacterium ulcerans. Growth...
6.
DHOPLE A
Indian J Lepr
. 2000 Aug;
72(1):5-20.
PMID: 10935183
In 1991 World Health Organization proclaimed the goal of global elimination of leprosy as a public health problem by year 2000 by implementing multidrug therapy (MDT). Since then the prevalence...
7.
DHOPLE A, Ryon D
Microbios
. 2000 Mar;
101(399):81-8.
PMID: 10738981
In order to determine the reason for the slow growth of Mycobacterium leprae either in a host or in vitro, the growth characteristics of Mycobacterium tuberculosis were studied. The ATP...
8.
DHOPLE A
Microbios
. 2000 Jan;
98(390):113-21.
PMID: 10624009
Calmodulin-like protein has been established as the primary receptor for calcium in eukaryotic as well as prokaryotic cells. The calmodulin-calcium complex regulates a variety of enzymes including nucleotide phosphodiesterase. Recently,...
9.
DHOPLE A
Int J Antimicrob Agents
. 1999 Sep;
12(4):319-23.
PMID: 10493608
The antimicrobial effects of a new dihydrofolate reductase inhibitor, epiroprim, alone and in combination with dapsone and brodimoprim against Mycobacterium leprae were evaluated in vitro in cell-free culture system. Two...
10.
DHOPLE A
Arzneimittelforschung
. 1999 Apr;
49(3):267-71.
PMID: 10219472
The antimicrobial effects of a new dihydrofolate reductase inhibitor, K-130 (2,4-diaminodiphenyl sulfone substituted 2,4-diamino-5-benzylpyrimidine), alone and in combination with dapsone (CAS 80-08-0) against both dapsone-sensitive and dapsone-resistant strains of Mycobacterium...